Publications:

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Mabs

Fu, Wenyan W; Wang, Yuxiao Y; Zhang, Yunshan Y; Xiong, Lijuan L; Takeda, Hiroaki H; Ding, Li L; Xu, Qunfang Q; He, Lidong L; Tan, Wenlong W; Bethune, Augus N AN; Zhou, Lijun L

Publication Date: 2014

Variant appearance in text: EGFR: F359A

PubMed Link: 24838231

Variant Present in the following documents:

• Main text

View BVdb publication page

The energy landscape analysis of cancer mutations in protein kinases.

Plos One

Dixit, Anshuman A; Verkhivker, Gennady M GM

Publication Date: 2011

Variant appearance in text: EGFR: F359A

PubMed Link: 21998754

Variant Present in the following documents:

View BVdb publication page

Mechanisms of drug resistance in kinases.

Expert Opinion On Investigational Drugs

Barouch-Bentov, Rina R; Sauer, Karsten K

Publication Date: 2011-02

Variant appearance in text: EGFR: F359A

PubMed Link: 21235428

Variant Present in the following documents:

• Main text

View BVdb publication page

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Therapeutics And Clinical Risk Management

Henkes, Martin M; van der Kuip, Heiko H; Aulitzky, Walter E WE

Publication Date: 2008-02

Variant appearance in text: EGFR: Phe359Ala

PubMed Link: 18728706

Variant Present in the following documents:

• Main text
• tcrm-0401-163.pdf

View BVdb publication page